Thomas Steyer’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Thomas Steyer’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-21,400,000	Closed	-$14.8M	–	257
2020 Q4	$14.8M	Sell	21,400,000 -22,673,000	-51%	-$48.3M	0.09%	98
2020 Q3	$99.2M	Sell	44,073,000 -127,000	-0.3%	-$363K	0.69%	44
2020 Q2	$158M	Buy	44,200,000 +9,000,000	+26%	+$32.5M	1.27%	31
2020 Q1	$134M	Buy	35,200,000 +4,825,050	+16%	+$15.9M	1.15%	30
2019 Q4	$91.4M	Buy	+30,374,950	New	+$79M	0.62%	38

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Thomas Steyer's BMY.RT Position: Q1 2021 in Review

Thomas Steyer sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 21,400,000 shares — an estimated $14.8M sold.

Thomas Steyer first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $158M in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Thomas Steyer reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Thomas Steyer sold 21,400,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $14.8M.
Thomas Steyer first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Thomas Steyer's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $158M in Q2 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Farallon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.